Unjha Formulations Ltd Stock Price Today (NSE: UNJHAFOR)
Fundamental Score
Unjha Formulations Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Unjha Formulations Ltd share price today is ₹24.25, up +1.68% on NSE/BSE as of 7 August 2026. Unjha Formulations Ltd (UNJHAFOR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.10 (Cr). The 52-week high for UNJHAFOR share price is ₹29.20 and the 52-week low is ₹17.52. At a P/E ratio of 17.29x, UNJHAFOR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 20.06% and a debt-to-equity ratio of 0.00.
Unjha Formulations Ltd Share Price Chart — NSE/BSE Historical Performance
Unjha Formulations Ltd share price chart: 36.97% return over the past month. 52-week high ₹29.20, 52-week low ₹17.52.
Unjha Formulations Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹24.13 | ₹24.25 | ₹23.90 | ₹24.25 | 6.94K (Cr) | |
| ₹25.09 | ₹25.09 | ₹23.85 | ₹23.85 | 8.63K (Cr) | |
| ₹25.10 | ₹25.16 | ₹25.10 | ₹25.10 | 4.29K (Cr) | |
| ₹28.45 | ₹28.45 | ₹26.06 | ₹26.20 | 7.01K (Cr) | |
| ₹29.20 | ₹29.20 | ₹28.75 | ₹28.75 | 13.09K (Cr) | |
| ₹28.00 | ₹28.00 | ₹26.01 | ₹26.01 | 4.72K (Cr) | |
| ₹25.00 | ₹28.99 | ₹25.00 | ₹27.50 | 14.67K (Cr) | |
| ₹24.80 | ₹24.80 | ₹24.60 | ₹24.79 | 1.61K (Cr) | |
| ₹22.51 | ₹24.74 | ₹22.51 | ₹24.74 | 911.00 (Cr) | |
| ₹22.02 | ₹23.89 | ₹22.02 | ₹23.81 | 6.64K (Cr) |
Unjha Formulations Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹29.20 | ₹29.20 | ₹23.85 | ₹24.25 | -16.95% | |
| ₹19.99 | ₹28.99 | ₹17.60 | ₹26.01 | +30.12% | |
| ₹19.50 | ₹21.20 | ₹17.52 | ₹19.85 | +1.79% | |
| ₹21.50 | ₹21.50 | ₹18.72 | ₹19.50 | -9.30% | |
| ₹21.50 | ₹22.94 | ₹18.60 | ₹22.00 | +2.33% | |
| ₹21.90 | ₹22.40 | ₹19.00 | ₹20.29 | -7.35% | |
| ₹22.50 | ₹23.90 | ₹20.50 | ₹21.69 | -3.60% | |
| ₹25.00 | ₹26.00 | ₹20.11 | ₹22.00 | -12.00% | |
| ₹25.95 | ₹26.00 | ₹23.22 | ₹25.00 | -3.66% | |
| ₹24.00 | ₹27.80 | ₹22.11 | ₹25.68 | +7.00% | |
| ₹25.00 | ₹25.50 | ₹23.00 | ₹24.00 | -4.00% | |
| ₹24.82 | ₹27.40 | ₹24.00 | ₹25.43 | +2.46% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap ayurvedic play with negative free cash flow and high illiquidity risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The stock sank to a 52-week low on April 7, 2026. However, promoter shareholding remains stable at 36.92% as of April 1, 2026.
CORE STORY (THE REAL GAME)
- Low P/E relative to industry
- Recent profit growth in Q3FY26
- Stable promoter holding
- Sustained revenue and profit growth
- New product launches
- Increased market awareness of ayurvedic products
- Micro-cap illiquidity
- Negative free cash flow
- Low operating profit margin
- Dependence on single product (isabgol)
Promoter holding steady at 36.92%, no FII/DII interest.
Indian pharma sector projected to reach $130 billion by 2030, but Unjha's micro-cap status means it may not benefit.
No. Free Cash Flow 5Y: ₹-0.16 Cr
If Unjha can diversify its product line and improve its cash flow, it could be a long-term compounder. But for now, it's too risky.
Primary Thesis Risk
Illiquidity will trap you.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Unjha Formulations Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Unjha Formulations Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of UNJHAFOR across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (20.06%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.79%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 17.29 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (36.48%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (47.58% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (47.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (97.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Margin Pressure Concerns (3.92%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-80.49%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Unjha Formulations Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Unjha Formulations Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Unjha Formulations LtdUnjha Formulati...Selected✓ UNJHAFOR • 531762 | 55.7/100 | ₹24.25₹24 | ₹12.10₹12.10 | 17.29Average 17.3 Average | 20.06%Excellent 20.06% Excellent | 27.79%Excellent 27.79% Excellent | 0.00Excellent 0.0 Excellent | 47.58%Excellent 47.58% Excellent | 9.60%Good 9.60% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Unjha Formulations Ltd PE Ratio History
Historical price-to-earnings ratio for UNJHAFOR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.91 | ₹25.00 | 27.5x |
| FY 2024 | ₹0.62 | ₹30.37 | 49x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Unjha Formulations Ltd Quarterly Performance
Latest quarterly metrics for UNJHAFOR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
36.48%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-80.49%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.60%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
47.58%
Compounded annual net profit growth over 5 years
Unjha Formulations Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for UNJHAFOR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Unjha Formulations Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Unjha Formulations Ltd (UNJHAFOR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Unjha Formulations Ltd
About UNJHAFOR (Unjha Formulations Ltd)
Unjha Formulations Ltd is a distinguished player in the Indian pharmaceutical landscape, deeply rooted in the ancient wisdom of Ayurveda. The company is committed to crafting and d...istributing a range of traditional health and wellness products, primarily focused on leveraging the therapeutic potential of natural ingredients. With a strong emphasis on quality and efficacy, Unjha Formulations aims to provide accessible and reliable Ayurvedic solutions to meet the diverse healthcare needs of the Indian population. Their commitment to preserving and promoting this time-tested system of medicine is evident in their dedication to sourcing the finest raw materials and employing rigorous manufacturing processes. Unjha Formulations strives to bridge the gap between traditional healing practices and modern pharmaceutical standards. The company's flagship offerings revolve around the widely recognized benefits of Isabgol, a natural dietary fiber. Unjha Formulations innovatively presents Isabgol in palatable and convenient formats, catering to consumer preferences. They expertly blend the inherent benefits of this natural ingredient with appealing flavors, creating user-friendly products designed to support digestive health and overall well-being. This approach allows Unjha Formulations to effectively reach a broader audience, making the advantages of Ayurveda more accessible and enjoyable. Through a dedication to innovation and consumer-centric product development, they have solidified their position as a trusted provider of natural health solutions within the competitive Indian market. Furthermore, Unjha Formulations extends its reach beyond domestic borders through its export operations. By sharing the benefits of authentic Ayurvedic products with international markets, the company contributes to the growing global recognition and acceptance of traditional Indian medicine. This expansion strategy not only strengthens the company's financial standing but also showcases the rich heritage of Indian healthcare practices on a worldwide stage. From its base in Sidhpur, India, Unjha Formulations continues to build upon its legacy of providing quality Ayurvedic products, driven by a commitment to innovation, ethical practices, and the well-being of its consumers.
Company Details
Key Leadership
UNJHAFOR Share Price: Frequently Asked Questions
What is the current share price of Unjha Formulations Ltd?
Unjha Formulations Ltd (UNJHAFOR) trades at ₹24.25 on NSE and BSE. Market cap ₹12.10 (Cr). Educational data only.
What is the P/E ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd has a P/E of 17.29x vs industry average 34.89x.
What is the Bull Run score for Unjha Formulations Ltd?
Unjha Formulations Ltd has a Bull Run score of 55.7/100 based on 25+ financial parameters.
Does Unjha Formulations Ltd pay dividends?
Unjha Formulations Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Unjha Formulations Ltd?
Unjha Formulations Ltd has ROE of 20.06%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd has debt-to-equity of 0.00.
Is Unjha Formulations Ltd a good investment?
Bull Run gives Unjha Formulations Ltd a score of 55.7/100. This is not investment advice — consult a SEBI-registered advisor.